Plain-language summary

This Phase 2 trial is studying Benvitimod Cream and Placebo cream for people with cutaneous T-cell lymphoma (skin lymphoma). Patients are randomly assigned to different treatment groups to see which approach works best. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years or older
• See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Benvitimod Cream (DRUG): Applied topically to the randomly assigned target lesion (left or right side) once daily for up to 24 weeks. The application area will not exceed 2% of the body surface area. | Placebo cream (DRUG): A vehicle cream matching the appearance of benvitimod cream. Applied topically to the contralateral target lesion once daily for up to 24 weeks.

Drugs / treatments

Benvitimod Cream, Placebo cream

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details